Neuropsychiatric manifestations in systemic lupus erythematosus: Epidemiology, pathophysiology and management

CNS Drugs

Volumn 25, Issue 9, 2011, Pages 721-736

  Postal, Mariana ^a   Costallat, Lilian T L ^a   Appenzeller, Simone ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

.; Anticoagulants; Antidepressants; Antiepileptic drugs; Antipsychotics; Corticosteroids; Immunosuppressants; Neurological disorders; Psychiatric disorders; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; ENDOTHELIUM ANTIBODY; GANGLIOSIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NERVE CELL ANTIBODY; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; PROTEIN S100B; RIBOSOME P ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; ANXIETY DISORDER; ARTICLE; ASEPTIC MENINGITIS; BRAIN BLOOD VESSEL; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CHOREA; CLINICAL EXAMINATION; CLINICAL FEATURE; COGNITIVE DEFECT; COGNITIVE REHABILITATION; COMBINATION CHEMOTHERAPY; CONSERVATIVE TREATMENT; DEMENTIA; DEMYELINATING DISEASE; DEPRESSION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FATIGUE; GUILLAIN BARRE SYNDROME; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPOTENSION; INCONTINENCE; ISCHEMIC OPTIC NEUROPATHY; JC VIRUS INFECTION; LABORATORY TEST; LEUKOPENIA; LOW DRUG DOSE; MICROVASCULATURE; MONOTHERAPY; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELITIS; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS SYNDROME; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGANIC BRAIN SYNDROME; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSYCHOEDUCATION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK FACTOR; SEIZURE; SENSORIMOTOR NEUROPATHY; SERUM SICKNESS; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL CORD DISEASE; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; VIRUS INFECTION; VIRUS REACTIVATION; WORK DISABILITY;

ANIMALS; CEREBELLUM; HUMANS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052180577     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11591670-000000000-00000     Document Type: Article

References (142)

1. Kozora E, Arciniegas DB, Filley CM, et al. Cognition, MRS neurometabolites, and MRI volumetrics in nonneuropsychiatric systemic lupus erythematosus: preliminary data. Cogn Behav Neurol 2005; 18: 159-62 (Pubitemid 41407452)
2. West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994; 20: 129-58 (Pubitemid 24066015)
3. Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. JRheumatol 1992; 19: 732-41
4. Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) 1968; 47: 337-69
5. Hanly JG. Neuropsychiatric lupus. Rheum Dis Clin North Am 2005; 31: 273-98, vi (Pubitemid 40732489)
6. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7 (Pubitemid 13221242)
7. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608
8. Ainiala H, Loukkola J, Peltola J, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57: 496-500 (Pubitemid 32757599)
9. Brey RL. Neuropsychiatric lupus: clinical and imaging aspects. Bull NYU Hosp Jt Dis 2007; 5: 194-9 (Pubitemid 351412132)
10. Hanly JG, Fisk JD, McCurdy G, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 2005; 32: 1459-6
11. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol 2010; 6: 358-67
12. Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58: 1214-20 (Pubitemid 34411865)
13. Hanly JG, McCurdy G, Fougere L, et al. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004; 31: 2156-62 (Pubitemid 39453234)
14. Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007; 56: 265-73 (Pubitemid 46106200)
15. Sibbitt Jr WL, Brandt JR, Johnson CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002; 29: 1536-42 (Pubitemid 34755624)
16. Harel L, Sandborg C, Lee T, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol 2006; 33: 1873-7 (Pubitemid 44373226)
17. Yu HH, Lee JH, Wang LC, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus 2006; 15: 651-7
18. Kivity S, Tsarfaty G, Agmon-Levin N, et al. Abnormal olfactory function demonstrated by manganese-enhanced MRI in mice with experimental neuropsychiatric lupus. Ann N Y Acad Sci 2010; 1193: 70-7
19. Maciaszczyk K, Durko T, Waszczykowska E, et al. Auditory function in patients with systemic lupus erythematosus. Auris Nasus Larynx 2011; 38: 26-32
20. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford) 2004; 43: 1555-60 (Pubitemid 39642582)
21. Sibley JT, Olszynski WP, Decoteau WE, et al. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992; 19: 47-52
22. Feinglass EJ, Arnett FC, Dorsch CA, et al. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore) 1976; 55: 323-39
23. Jonsen A, Bengston AA, Nived O, et al. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology 2002; 41: 1308-12 (Pubitemid 35363807)
24. Panopalis P, Julian L, Yazdany J, et al. Impact of memory impairment on employment status in persons with systemic lupus erythematosus. Arthritis Rheum 2007; 57: 1453-60 (Pubitemid 350308844)
25. Baker K, Pope J. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology (Oxford) 2009; 48: 281-4
26. Appenzeller S, Cendes F, Costallat LT. Cognitive impairment and employment status in systemic lupus erythematosus: a prospective longitudinal study. Arthritis Rheum 2009; 61: 680-7
27. Kovacs JA, Urowitz MB, Gladman DD. Dilemmas in neuropsychiatric lupus. Rheum Dis Clin North Am 1993; 19: 795-814 (Pubitemid 23347412)
28. Hanly JG, Su L, Farewell V, et al. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol 2009; 36: 1449-59
29. Hanly JG, Urowitz MB, Jackson D, et al. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011; 70: 961-7
30. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074-82
31. Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus.Neurology 2004; 63: 1808-12 (Pubitemid 39532373)
32. Appenzeller S, Cendes F, Costallat LT. Acute psychosis in systemic lupus erythematosus. Rheumatol Int 2008; 28: 237-43 (Pubitemid 350265464)
33. Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford) 2008; 47: 1498-502
34. Hanly JG, Harrison MJ. Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol 2005 Oct; 19 (5): 799-821 (Pubitemid 41258584)
35. Appenzeller S, Costallat LT. Clinical implications of migraine in systemic lupus erythematosus: relation to cumulative organ damage. Cephalalgia 2004; 24: 1024-30 (Pubitemid 39577568)
36. Davey R, Bamford J, Emery P. The ACR classification criteria for headache disorders in SLE fail to classify certain prevalent headache types. Cephalalgia 2008; 28: 296-9 (Pubitemid 351172033)
37. Ainiala H, Hietaharju A, Loukkola J, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001; 45: 419-23 (Pubitemid 32979846)
38. Zhou HQ, Zhang FC, Tian XP, et al. Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients. Lupus 2008; 17: 93-9 (Pubitemid 351346442)
39. Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin 2010; 28: 61-73
40. Joseph FG, Scolding NJ. Neurolupus. Pract Neurol 2010; 10: 4-15
41. Bessant R, Hingorani A, Patel L, et al. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 924-9 (Pubitemid 38996970)
42. Seawell AH, Danoff-Burg S. Psychosocial research on systemic lupus erythematosus: a literature review. Lupus 2004; 13: 891-9 (Pubitemid 39664946)
43. Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009; 61: 822-9
44. Appenzeller S, Veilleux M, Clarke A. Third cranial nerve palsy or pseudo 3rd nerve palsy of myasthenia gravis? A challenging diagnosis in systemic lupus erythematosus. Lupus 2009; 18: 836-40
45. Carlomagno S,Migliaresi S, Ambrosone L, et al. Cognitive impairment in systemic lupus erythematosus: a follow-up study. J Neurol 2000; 247: 273-9 (Pubitemid 30223964)
46. Karassa FB, Ioannidis JP, Boki KA, et al. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 2000; 109: 628-34
47. Appenzeller S, Carnevalle AD, Li LM, et al. Hippocampal atrophy in systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 1585-9 (Pubitemid 44799669)
48. Hanly JG, Fisk JD, Sherwood G, et al. Clinical course of cognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1994; 2: 1825-31 (Pubitemid 24312642)
49. Hay EM, Huddy A, Black D, et al. A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. Ann Rheum Dis 1994; 53: 298-303 (Pubitemid 24164972)
50. WaterlooK, Omdal R, Husby G, et al. Neuropsychological function in systemic lupus erythematosus: a five-year longitudinal study. Rheumatology (Oxford) 2002; 41: 411-5 (Pubitemid 34537839)
51. Petri M, Naqibuddin M, Carson KA, et al. Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. J Rheumatol 2008; 35: 2348-54
52. Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988; 23: 380-4 (Pubitemid 18098245)
53. Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955-1977. Sem Arthritis Rheum 1979; 8: 212-21 (Pubitemid 9104125)
54. Zvaifler NJ, Bluestein HG. The pathogenesis of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 862-6 (Pubitemid 12022165)
55. Abbott NJ, Mendonca LL, Dolman DE. The blood-brain barrier in systemic lupus erythematosus. Lupus 2003; 12: 908-15 (Pubitemid 38082086)
56. Brooks WM, Sibbitt Jr WL, Kornfeld M, et al. The histopathologic associates of neurometabolite abnormalities in fatal neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2010; 62: 2055-63
57. Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus: interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996; 39: 9-22
58. Appenzeller S, Amorim BJ, Ramos CD, et al. Voxel-based morphometry of brain SPECT can detect the presence of active central nervous system involvement in systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46: 467-72 (Pubitemid 46344660)
59. Appenzeller S, Li LM, Costallat LT, et al. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study. Brain 2005; 128: 2933-40 (Pubitemid 41746646)
60. Postal M, Appenzeller S. Central nervous system manifestations in systemic lupus erythematosus: diagnosis to treatment. In: Columbus F, editor. Autoimmune diseases: symptoms, diagnosis and treatment. New York (NY): Nova Science Publishers, Inc., 2001: 209-31
61. Karpiak SE, Graf L, Rapport MM. Antiserum to brain gangliosides produces recurrent epileptiform activity. Science 1976; 194: 735-7
62. Zaccagni H, Fried J, Cornell J, et al. Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage. Front Biosci 2004; 9: 1654-9 (Pubitemid 38918623)
63. Matsuda J, Gohchi K, Gotoh M, et al. Circulating intercellular adhesion molecule-1 and soluble interleukin 2-receptor in patients with systemic lupus erythematosus. Eur J Haematol 1994; 52: 302-3 (Pubitemid 24207990)
64. Sfikakis PP, Charalambopoulos D, Vayiopoulos G, et al. Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12: 5-9
65. Spronk PE, Bootsma H, Huitema MG, et al. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Rheumatol 1994; 97: 439-44 (Pubitemid 24283887)
66. Trysberg E, Carlsten H, Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000; 9: 498-503
67. Shiozawa S, Kuroki Y, Kim M, et al. Interferon-alpha in lupus psychosis. Arthritis Rheum 1992; 35: 417-22
68. Faber-Elmann A, Sthoeger Z, Tcherniack A, et al. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 2002; 127: 393-8 (Pubitemid 34233949)
69. Ainiala H, Hietaharju A, Dastidar P, et al. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum 2004; 50: 858-65 (Pubitemid 38326186)
70. Hirohata S, Kanai Y, Mitsuo A, et al., NPSLE Research Subcommittee. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis: a multicenter retrospective study. Clin Rheumatol 2009; 28: 1319-23
71. Okamoto H, Kobayashi A, Yamanaka H. Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus. J Biomed Biotechnol. Epub 2010 Jun 29
72. Aranow C, Diamond B, Mackay M. Glutamate receptor biology and its clinical significance in neuropsychiatric systemic lupus erythematosus. Rheum Dis Clin North Am 2010; 36: 187-201
73. Sabet A, Sibbitt Jr WL, Stidley CA, et al. Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 1998; 29: 2254-60 (Pubitemid 28511941)
74. Afeltra A, Garzia P, Mitterhofer AP, et al. Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 2003; 61: 108-10 (Pubitemid 36818758)
75. Pierangeli SS, Harris EN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus 1994; 3: 247-51 (Pubitemid 24277035)
76. Katsiari CG, Giavri I, Mitsikostas DD, et al. Acute transverse myelitis and antiphospholipid antibodies in lupus: no evidence for anticoagulation. Eur J Neurol 2011; 18: 556-63
77. Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54: 312-24 (Pubitemid 43122215)
78. Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41: 1357-66 (Pubitemid 36004311)
79. Ghirardello A, Briani C, Lucchetta M, et al. Antiribosomal P protein antibodies and neuropsychiatric systemic lupus erythematosus: cross-sectional vs. prospective studies. Lupus 2010; 19: 771-3
80. Mostafa GA, Ibrahim DH, Shehab AA, et al. The role of measurement of serum autoantibodies in prediction of pediatric neuropsychiatric systemic lupus erythematosus. J Neuroimmunol 2010; 227: 195-201
81. Nery FG, Borba EF, Viana VS, et al. Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 695-700 (Pubitemid 351312367)
82. Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317: 265-71 (Pubitemid 17100105)
83. Hanly JG, Urowitz MB, Siannis F, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008; 58: 843-53 (Pubitemid 351364883)
84. Kobiler D, Allweis C. The effect of antisynaptosomal plasma membrane antibodies on memory. Brain Res 1976; 115: 129-38
85. Morris RG, Anderson E, Lynch GS, et al. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 1986; 319: 774-6 (Pubitemid 16145031)
86. Skerry TM, Genever PG. Glutamate signalling in nonneuronal tissues. Trends Pharmacol Sci 2001; 22: 174-81
87. DeGiorgio LA, Konstantinov KN, Lee SC, et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001; 7: 1189-93 (Pubitemid 33063773)
88. Lapteva L, Nowak M, Yarboro CH, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2505-14 (Pubitemid 44205011)
89. Omdal R, Brokstad K, WaterlooK, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005; 12: 392-8 (Pubitemid 40524182)
90. Emmer BJ, van der Grond J, Steup-Beekman GM, et al. Selective involvement of the amygdala in systemic lupus erythematosus. PLoS Med 2006; 3: e499
91. Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006; 33: 1553-8 (Pubitemid 44168826)
92. Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2515-22 (Pubitemid 44205012)
93. Steup-Beekman G, Steens S, van Buchem M, et al. Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus 2007; 16: 329-34 (Pubitemid 47074834)
94. Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008; 58: 1130-5 (Pubitemid 351564016)
95. Yoshio T, Onda K, Nara H, et al. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2006; 54: 675-8 (Pubitemid 43228647)
96. Fragoso-Loyo H, Cabiedes J, Orozco-Narvaez A, et al. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus: implications for diagnosis and pathogenesis. PLoS One 2008; 3: e3347
97. Conti F, Alessandri C, Bompane D, et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for antiendothelial-cell Abs. Arthritis Res Ther 2004; 6: 366-72
98. Song J, Park YB, Lee WK, et al. Clinical associations of anti-endothelial cell Abs in patients with systemic lupus erythematosus. Rheumatol Int 2000; 20: 1-7
99. Schenatto CB, Xavier RM, Bredemeier M, et al. Raised serum S100B protein levels in neuropsychiatric lupus. Ann Rheum Dis 2006; 65: 829-31 (Pubitemid 43799188)
100. Yang XY, Lin J, Lu XY, et al. Expression of S100B protein levels in serum and cerebrospinal fluid with different forms of neuropsychiatric systemic lupus erythematosus. Clin Rheumatol 2008; 27: 353-7
101. Costallat LT, de Oliveira RM, Santiago MB, et al. Neuropsychiatric manifestations of systemic lupus erythematosus: the value of anticardiolipin, antigangliosides and antigalactocerebrosides antibodies. Clin Rheumatol 1990; 9: 489-97
102. Jonsen A, Bengtsson AA, Nived O, et al. The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles. Lupus 2003; 12: 846-50 (Pubitemid 37463102)
103. Small P, Mass MF, Kohler PF, et al. Central nervous system involvement in SLE: diagnostic profile and clinical features. Arthritis Rheum 1977; 20: 869-78
104. Trysberg E, Nylen K, Rosengren LE, et al. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003; 48: 2881-7 (Pubitemid 37280617)
105. Appenzeller S, Pike GB, Clarke AE. Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allergy Immunol 2008; 34: 361-6
106. Appenzeller S, Rondina JM, Li LM, et al. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2783-9 (Pubitemid 41369107)
107. Appenzeller S, Bonilha L, Rio PA, et al. Longitudinal analysis of gray and white matter loss in patients with systemic lupus erythematosus. Neuroimage 2007; 34: 694-701 (Pubitemid 44827765)
108. Appenzeller S, Vasconcelos Faria A, Li LM, et al. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol 2008; 64: 635-43
109. Luyendijk J, Steens SC, Ouwendijk WJ, et al. Neuropsychiatric SLE: lessons learned from MRI. Arthritis Rheum 2011; 63: 722-32
110. Rovaris M, Viti B, Ciboddo G, et al. Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. J Neurol Neurosurg Psychiatry 2000; 68: 170-7 (Pubitemid 30245839)
111. Bosma GP, Rood MJ, Zwinderman AH, et al. Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging. Arthritis Rheum 2000; 43: 48-54 (Pubitemid 30368212)
112. Moritani T, Shrier DA, Numaguchi Y, et al. Diffusionweighted echo-planar MR imaging of CNS involvement in systemic lupus erythematosus. Acad Radiol 2001; 8: 741-53 (Pubitemid 32717679)
113. Demaerel P, De Ruyter N, Maes F, et al. Magnetic resonance angiography in suspected cerebral vasculitis. Eur Radiol 2004; 14: 1005-12 (Pubitemid 38787245)
114. Efthimiou P, Blanco M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod Rheumatol 2009; 19: 457-68
115. Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 2003; 12: 935-42 (Pubitemid 38082090)
116. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 620-5 (Pubitemid 40469095)
117. Mok CC, Lau CS, Wong RW. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med 2003; 115: 59-62 (Pubitemid 36831123)
118. Cuadrado MJ, Khamashta MA, Ballesteros A, et al. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000; 79: 57-68 (Pubitemid 30077737)
119. Baca V, Lavalle C, Garcia R, et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 1999; 26: 432-9 (Pubitemid 29066751)
120. Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001; 10: 140-7 (Pubitemid 32410067)
121. Boumpas DT, Yamada H, Patronas NJ, et al. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 1991; 81: 975-84
122. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10: 154-61 (Pubitemid 32410070)
123. Ramos PC, Mendez MJ, Ames PR, et al. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14: 295-9 (Pubitemid 26290870)
124. Sakic B, Kolb B, Whishaw IQ, et al. Immunosuppression prevents neuronal atrophy in lupus-prone mice: evidence for brain damage induced by autoimmune disease? J Neuroimmunol 2000; 111: 93-101
125. Xu J, Cheng Y, Chai P, et al. White-matter volume reduction and the protective effect of immunosuppressive therapy in systemic lupus erythematosus patients with normal appearance by conventional magnetic resonance imaging. Rheumatol 2010; 37: 974-86
126. Schroeder JO, Euler HH. Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Adv ExpMed Biol 1989; 260: 203-13
127. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55
128. Hughes RA, Raphael JC, Swan AV, et al. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2001; (2): CD002063
129. Sherer Y, Levy Y, Langevitz P, et al. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 1999; 18: 170-3 (Pubitemid 29223043)
130. Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992; 10: 391-3
131. Valesini G, Priori R, Francia A, et al. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol 1994; 16: 313-21
132. Dong Y, Zhang X, Tang F, et al. Intrathecal injection with methotrexate plus dexamethasone in the treatment of central nervous system involvement in systemic lupus erythematosus. Chin Med J (Engl) 2001; 114: 764-6 (Pubitemid 32769521)
133. Grisanti M, Nader A, Cacciuttolo R. Central nervous system involvement due to systemic lupus erythematosus/antiphospholipid syndrome: successful treatment with mycophenolate mofetil. Lupus 2001; 10: S31
134. Dall'Era M, Wofsy D. Biologic therapy for systemic lupus erythematosus. Discov Med 2010; 9: 20-3
135. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470-5 (Pubitemid 46580466)
136. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-33
137. Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2010; 29: 707-16
138. Turner-Stokes T, Lu TY, Ehrenstein MR, et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) 2011; 50: 1401-8
139. Genentech, Inc. and Biogen Idec. Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint [online]. Available from URL: http://www.newsmedical.net/news/2009/03/11/46787.aspx [Accessed 2011 Jul 4]
140. Heinlein AC, Gertner E. Marked inflammation in catastrophic longitudinal myelitis associated with systemic lupus erythematosus. Lupus 2007; 16: 823-6 (Pubitemid 350069796)
141. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8 (Pubitemid 37122325)
142. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57: 1487-95 (Pubitemid 350308848)